Cyprus Health Minister Neophytos Charalambides underscored the importance of early diagnosis and intervention for children with rare genetic diseases during an event hosted by the Pancyprian Association for Rare Genetic Conditions “Unique Smiles.”
Speaking at the conference, held under the auspices of the Health Ministry, Charalambides said rare diseases have a profound impact on patients’ physical health, emotional well‑being and social functioning.
Delayed diagnosis, uncertainty about disease progression and financial strain often increase anxiety and isolation, he noted, adding that lack of public awareness can lead to stigma.
The minister said Cyprus has been investing in rare‑disease care through its National Strategy, in place since 2012 and currently under review to align with scientific and European developments.
He highlighted the role of the national health system (GeSY) and access to orphan drugs approved by the European Medicines Agency, supported by the Health Insurance Organization, the Pharmaceutical Services and the ministry.
Charalambides also pointed to Cyprus’ role as chair of the EU Council, saying the country is promoting a resilient European pharmaceutical policy focused on innovation and equitable access.
Participation in European Reference Networks, he added, strengthens cross‑border cooperation and improves access to specialized expertise.
He praised patient associations as essential advocates, noting that “Unique Smiles” plays a key role in supporting families, facilitating communication with state services and European groups, and helping resolve issues related to prevention, diagnosis, treatment and social inclusion. He also highlighted the establishment of the Multidisciplinary Center in 2021 as a major step in providing comprehensive care.
Charalambides thanked the organizers, speakers and participants, saying the event would contribute to meaningful dialogue and closer cooperation among all stakeholders.
